A combination of talazoparib and enzalutamide, also known as talzenna and xtandi, has been found to delay progression of prostate cancer. The treatment appears to be effective in patients with metastatic prostate cancer, including those with certain genetic mutations. The combination has shown improved outcomes in terms of progression-free survival in various studies, although the specific details and contexts of these findings are not entirely clear.